LabCorp Extends Orchid Bid Again - Analyst Blog
December 02 2011 - 10:15AM
Zacks
Laboratory Corporation of
America Holdings (LH) has once again extended the tender
offer for Orchid Cellmark (ORCH) until December 9,
2011. The company had earlier extended the tender offer to November
30.
In May 2011, the company received a
request from the Federal Trade Commission (FTC) for some additional
information related to the transaction. LabCorp is cooperating with
the FTC on this issue. To date, about 88.2% of the outstanding
shares of Orchid have been tendered.
LabCorp had decided in April 2011
to acquire Orchid Cellmark for $2.80 per share, coming to a total
consideration of $85.4 million, all in cash. After taking into
account Orchid Cellmark’s cash balance, LabCorp’s net payable comes
to $65.6 million. Orchid Cellmark provides DNA testing services
targeted towards forensic and family relationship applications on a
global basis.
This deal would enable LabCorp to
command a leading position in identity testing in the US and also
establish its presence in this field in the UK. LabCorp derives 60%
of its revenues from core routine tests. It also provides specialty
testing services in the areas of allergy, clinical trials,
diagnostic genetics, identity, forensics, infectious disease,
oncology and occupational testing, which accounts for the remaining
40%.
LabCorp, in a drive to diversify
from the more mature core testing, has of late put more and more
emphasis on specialized testing. Acquisitions have played an
integral role in this respect, significant among which are Monogram
Bioscience (August 2009) and Genzyme Genetics (December 2010). The
company has set a target of garnering 45% of its revenues from the
specialty business in the next 3-5 years.
During the most recent quarter,
total revenue increased 10% year over year to reach $1,404.5
million, of which approximately 7% came from the acquisition of
Genzyme Genetics. However, economic uncertainty has resulted in
lackluster physician office visits, as reflected in the
year-to-date declining trend in organic volume growth at LabCorp
(3% in the first, 2% in the second and 1.2% in the third).
Moreover, with no significant job growth in the economy or an
increase in commercially insured covered lives, the company’s
overall volume growth will continue to languish until the economy
rebounds.
In this scenario, LabCorp’s
competitor, Quest Diagnostics (DGX), is also
striving for a greater share of the high-margined, specialized
testing business. In such a quest, the company has acquired
neurological diagnostic test specialist Athena Diagnostics and
Celera Corp.
We are currently Neutral on
LabCorp, which also corresponds with the Zacks #3 Rank (Hold) in
the short term. For Quest Diagnostics, we have a Neutral
recommendation.
QUEST DIAGNOSTC (DGX): Free Stock Analysis Report
LABORATORY CP (LH): Free Stock Analysis Report
ORCHID CELLMARK (ORCH): Free Stock Analysis Report
Zacks Investment Research
Orchid Cellmark (NASDAQ:ORCH)
Historical Stock Chart
From May 2024 to Jun 2024
Orchid Cellmark (NASDAQ:ORCH)
Historical Stock Chart
From Jun 2023 to Jun 2024